- Home
- CVAC vs SYRE Comparison
CVAC vs SYRE Comparison
Compare CVAC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- SYRE
- Stock Information
- Founded
- CVAC 2000
- SYRE 2013
- Country
- CVAC Germany
- SYRE United States
- Employees
- CVAC N/A
- SYRE N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- SYRE Health Care
- Exchange
- CVAC Nasdaq
- SYRE Nasdaq
- Market Cap
- CVAC 764.4M
- SYRE 841.4M
- IPO Year
- CVAC 2020
- SYRE 2016
- Fundamental
- Price
- CVAC $4.47
- SYRE $15.30
- Analyst Decision
- CVAC Strong Buy
- SYRE Buy
- Analyst Count
- CVAC 2
- SYRE 6
- Target Price
- CVAC $14.00
- SYRE $55.00
- AVG Volume (30 Days)
- CVAC 779.9K
- SYRE 490.0K
- Earning Date
- CVAC 05-20-2025
- SYRE 05-08-2025
- Dividend Yield
- CVAC N/A
- SYRE N/A
- EPS Growth
- CVAC N/A
- SYRE N/A
- EPS
- CVAC 0.87
- SYRE N/A
- Revenue
- CVAC $566,039,775.00
- SYRE N/A
- Revenue This Year
- CVAC N/A
- SYRE N/A
- Revenue Next Year
- CVAC $37.79
- SYRE N/A
- P/E Ratio
- CVAC $5.16
- SYRE N/A
- Revenue Growth
- CVAC 787.60
- SYRE N/A
- 52 Week Low
- CVAC $2.37
- SYRE $10.91
- 52 Week High
- CVAC $5.28
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- CVAC 65.61
- SYRE 51.16
- Support Level
- CVAC $3.35
- SYRE $14.87
- Resistance Level
- CVAC $4.80
- SYRE $15.71
- Average True Range (ATR)
- CVAC 0.30
- SYRE 0.72
- MACD
- CVAC 0.07
- SYRE 0.10
- Stochastic Oscillator
- CVAC 77.51
- SYRE 51.57
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.